The anticoagulant therapy for sepsis-associated disseminated intravascular coagulation

Thrombosis Research

Volumn 131, Issue 5, 2013, Pages 383-389

  Iba, Toshiaki ^a   Nagaoka, Isao ^a   Boulat, Marcel ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Activated Protein C; Antithrombin; Disseminated intravascular coagulation (DIC); Japanese Association for Acute Medicine (JAAM); Thrombomodulin; Tissue factor pathway inhibitor

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; DALTEPARIN; DANAPAROID; DROTRECOGIN; HEPARIN; HEPARINOID; PLACEBO; RECOMBINANT THROMBOMODULIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING DISORDER; COMMUNITY ACQUIRED PNEUMONIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG RECALL; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEMATOLOGIC MALIGNANCY; HUMAN; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SEPSIS; SEPTIC SHOCK; SURVIVAL;

ANIMALS; ANTICOAGULANTS; DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; SEPSIS; TREATMENT OUTCOME;

EID: 84877788998     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.03.012     Document Type: Review

References (68)

1. A. Kidokoro, T. Iba, M. Fukunaga, and Y. Yagi Alterations in coagulation and fibrinolysis during sepsis Shock 5 1996 223 228
2. G.R. Bernard, J.L. Vincent, P.F. Laterre, S.P. LaRosa, J.F. Dhainaut, and A. Lopez-Rodriguez Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 344 2001 699 709
3. B.L. Warren, A. Eid, P. Singer, S.S. Pillay, P. Carl, and I. Novak High-dose antithrombin III in severe sepsis. A randomized controlled trial JAMA 286 2001 1869 1878
4. E. Abraham, K. Reinhart, S. Opal, I. Demeyer, C. Doig, and A.L. Rodriguez Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial JAMA 290 2003 238 247
5. R.P. Dellinger, J.M. Carlet, H. Masur, H. Gerlach, T. Calandra, and J. Cohen Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock Crit Care Med 32 2004 858 873
6. V.M. Ranieri, B.T. Thompson, P.S. Barie, J.F. Dhainaut, I.S. Douglas, and S. Finfer Drotrecogin alfa (activated) in adults with septic shock N Engl J Med 366 2012 2055 2064
7. R.P. Dellinger, M.M. Levy, A. Rhodes, D. Annane, H. Gerlach, and S.M. Opal Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012 Crit Care Med 41 2013 580 637
8. N. Kobayashi, T. Maekawa, M. Takada, H. Tanaka, and H. Gonmori Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan Bibl Haematol 49 1983 265 275
9. F.B. Taylor Jr., C.H. Toh, W.K. Hoot, H. Wada, and M. Levi Toward definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation Thromb Haemost 86 2001 1327 1330
10. S. Gando, T. Iba, Y. Eguchi, Y. Ohtomo, K. Okamoto, and K. Koseki A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: Comparing current criteria Crit Care Med 34 2006 625 631
11. S. Gando, D. Saitoh, H. Ogura, T. Mayumi, K. Koseki, and T. Ikeda Disseminated intravascular coagulation (DIC) diagnosed based on the Japanese Association for Acute Medicine criteria is a dependent continuum to overt DIC in patients with sepsis Thromb Res 123 2009 715 718
12. M. Shimaoka, and E.J. Park Advances in understanding sepsis Eur J Anesthesiol Suppl 42 2008 146 153
13. S. Zeerleder, C.E. Hack, and W.A. Wuillemin Disseminated intravascular coagulation in sepsis Chest 128 2005 2864 2875
14. C.T. Esmon The interactions between inflammation and coagulation Br J Haematol 131 2005 417 430
15. A.A. Anas, W.J. Wiersinga, A.F. de Vos, and T. van der Poll Recent insights into the pathogenesis of bacterial sepsis Neth J Med 68 2010 147 152
16. G.T. Kinasewitz, S.B. Yan, B. Basson, P. Comp, J.A. Russell, and A. Cariou Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism Crit Care 8 2004 R82 R90
17. A.J. Chu Tissue Factor, blood coagulation, and beyond: An overview Int J Inflamm 2011 367284
18. R. Pawlinski, and N. Mackman Cellular sources of tissue factor in endotoxemia and sepsis Thromb Res 125 2010 S70 S73
19. M.E. Bianchi DAMPs, PAMPs and alarmins: all we need to know about danger J Leukoc Biol 81 2007 1 5
20. K. Kambas, I. Mitroulis, E. Apostolidou, A. Girod, A. Chrysanthopoulou, and I. Pneumatikos Autophagy mediates the delivery of thrombogenic tissue factor to neutrophil extracellular traps in human sepsis PLoS One 7 2012 e45427
21. N. Semeraro, C.T. Ammollo, F. Semeraro, and M. Colucci Sepsis, thrombosis and organ dysfunction Thromb Res 129 2012 290 295
22. J. Xu, X. Zhang, R. Pelayo, M. Monestier, C.T. Ammollo, and F. Semeraro Extracellular histones are major mediators of death in sepsis Nat Med 15 2009 1318 1321
23. A. Kidokoro, T. Iba, and J. Hong Role of DIC in multiple organ failure Int J Surg Investig 2 2000 73 80
24. M. Emonts, E.L. de Bruijne, A.H. Guimarães, P.J. Declerck, F.W. Leebeek, and M.P. de Maat Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children J Thromb Haemost 6 2008 268 276
25. F.B.J. Taylor, A. Chang, C.T. Esmon, A. D'Angelo, S. Vigano-D'Angelo, and K.E. Blick Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon J Clin Invest 79 1987 918 925
26. K. Murakami, K. Okajima, M. Uchiba, M. Johno, T. Nakagaki, and H. Okabe Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats Blood 87 1996 642 647
27. B. White, M. Schmidt, C. Murphy, W. Livingstone, D. O'Toole, and M. Lawler Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line Br J Haematol 110 2000 130 134
28. M. Levi, J. Dorffler-Melly, P.H. Reitsma, H.R. Buller, S. Florquin, and T. Poll Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein C deficient mice Blood 101 2003 4823 4827
29. C.T. Esmon New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins J Exp Med 196 2002 561 564
30. R.P. Dellinger, M.M. Levy, J.M. Carlet, J. Bion, M.M. Parker, and R. Jaeschke Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008 Crit Care Med 36 2008 296 327
31. C.T. Esmon, and H.P. Schwarz An update on clinical and basic aspects of the protein C anticoagulant pathway Trends Cardiovasc Med 5 1995 141 148
32. M.G. Vervloet, L.G. Thijs, and C.E. Hack Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock Semin Thromb Hemost 24 1998 33 44
33. A.F. Shorr, G.R. Bernard, J.F. Dhainaut, J.R. Russell, W.L. Macias, and D.R. Nelson Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome Crit Care 10 2006 R92 R99
34. M. Levi The coagulant response in sepsis Clin Chest Med 29 2008 627 642
35. L.O. Mosnier, B.V. Zlokovic, and J.H. Griffin The cytoprotective protein C pathway Blood 109 2007 3161 3172
36. B. Casserly, H. Gerlach, G.S. Phillips, J.C. Marshall, S. Lemeshow, and M.M. Levy Evaluating the use of recombinant human activated protein C in adult severe sepsis: results of the Surviving Sepsis Campaign Crit Care Med 40 2012 1417 1426
37. A.C. Kalil, and S.P. Larosa Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression Lancet Infect Dis 12 2012 678 686
38. T. Iba, and A. Kidokoro High dose antithrombin therapy for sepsis: Mechanism of action Shock 18 2002 389 394
39. J. Kienast, M. Juers, C.J. Wiedermann, J.N. Hoffmann, H. Ostermann, and R. Strauss Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation J Thromb Haemost 4 2006 90 97
40. J.N. Hoffmann, D. Muhlbayer, M. Jochum, and D. Inthorn Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis Crit Care Med 32 2004 1851 1859
41. J. Roemisch, E. Gray, J.N. Hoffmann, and C.J. Wiedermann Antithrombin. A new look at the actions of a serine protease inhibitor Blood Coagul Fibrinolysis 13 2002 657 670
42. T. Iba, D. Saito, H. Wada, and H. Asakura Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: A prospective multicenter survey Thromb Res 130 2012 e129 e133
43. M. Lamy, B. Eisele, and H.O. Keinecke Antithrombin III in patients with severe sepsis: a randomized placebo-controlled double blind multicenter trial Proceedings of the 9th European Congress on Intensive Care Medicine 1996 Monduzzi Editore Bologna, Italy 385 390
44. R.G. Wunderink, P.F. Laterre, B. Francois, D. Perrotin, A. Artigas, and L.O. Vidal Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial Am J Respir Crit Care Med 183 2011 1561 1568
45. C.T. Esmon The regulation of natural anticoagulant pathways Science 235 1987 1348 1352
46. T. Iba, K. Aihara, S. Watanabe, Y. Yanagawa, M. Takemoto, and A. Yamada Recombinat thrombomodulin improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat LPS model Thromb Res 131 2013 295 299
47. P.P. Nawroth, and D.M. Stern Modulation of endothelial cell hemostatic properties by tumor necrosis factor J Exp Med 163 1986 740 745
48. H. Saito, I. Maruyama, S. Shimazaki, Y. Yamamoto, N. Aikawa, and R. Ohno Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial J Thromb Haemost 5 2007 31 41
49. http://www.artisanpharma.net/news.htm
50. http://clinicaltrials.gov/ct2/show/NCT01598831?term=ART-123&rank=2
51. K.H. Polderman, and A.R.J. Girbes Drug intervention trials in sepsis: divergent results Lancet 363 2004 1721 1723
52. N. Sakuragawa, H. Hasegawa, M. Maki, M. Nakagawa, and M. Nakashima Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC)-a multicenter co-operative double-blind trial in comparison with heparin Thromb Res 72 1993 475 500
53. K. Yasunaga, N. Ogawa, K. Mori, N. Aoki, T. Matsuda, and M. Nakagawa Evaluation of clinical effect of danaparoid sodium (KB-101) on disseminated intravascular coagulation (DIC): double blind comparative study Jpn Pharmacol Ther 23 1995 2815 2834
54. S. Massberg, L. Grahl, M.L. von Bruehl, D. Manukyan, S. Pfeiler, and C. Goosmann Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases Nat Med 2010 887 896
55. T. Iba, A. Kidokoro, M. Fukunaga, K. Nagakari, A. Shirahama, and Y. Ida Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat LPS model Crit Care Med 33 2005 368 372
56. R. Nevière, A. Tournoys, S. Mordon, X. Maréchal, F.L. Song, and M. Jourdain Antithrombin reduces mesenteric venular leukocytes interactions and small intestine injury in endotoxemic rats Shock 15 2001 220 225
57. M. Levi, C.H. Toh, J. Thachil, and H.G. Watson Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology Br J Haematol 145 2009 24 33
58. H. Wada, H. Asakura, K. Okamoto, T. Iba, T. Uchiyama, and K. Kawasugi Expert consensus for the treatment of disseminated intravascular coagulation in Japan Thromb Res 125 2010 6 11
59. M. Di Nisio, F. Baudo, B. Cosmi, A. D'Angelo, A. De Gasperi, and A. Malato Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) Thromb Res 129 2011 e177 e184
60. T. Iba Japanese Association for Acute Medicine DIC Study Group. The meanings of DIC diagnostic criteria Thromb Res 129 2012 e269 e270
61. T. Iba, and H. Asakura Comparison between British and Japanese guidelines for the diagnosis and treatment of disseminated intravascular coagulation Br J Haematol 149 2010 461 462
62. S. Gando, D. Saitoh, H. Ogura, T. Mayumi, K. Koseki, and T. Ikeda Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey Crit Care Med 36 2008 145 150
63. J.F. Dhainaut, S.B. Yan, D.E. Joyce, V. Pettilä, B. Basson, and J.T. Brandt Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation J Thromb Haemost 2 2004 1924 1933
64. T. Iba, S. Gando, A. Murata, S. Kushimoto, D. Saitoh, and Y. Eguchi Predicting the severity of SIRS-associated coagulopathy with hemostatic molecular markers and vascular endothelial injury markers J Trauma 63 2007 1093 1098
65. T. Iba, Y. Yagi, A. Kidokoro, M. Fukunaga, and T. Fukunaga Increased plasma levels of soluble thrombomodulin in patients with sepsis and organ failure Surg Today 25 1995 585 590
66. J.F. Dhainaut, S.B. Yan, A. Cariou, and J.P. Mira Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis Crit Care Med 30 2002 S318 S324
67. T. Iba, E. Nakarai, T. Takayama, K. Nakajima, T. Sasaoka, and Y. Ohno Combination effect of antithrombin and recombinant human soluble thrombomodulin in an LPS induced rat sepsis model Crit Care 13 2009 R203 R209
68. J. Sunden-Cullberg, A. Norrby-Teglund, and C.J. Treutiger The role of high mobility group box-1 protein in severe sepsis Curr Opin Infect Dis 19 2006 231 236